AstraZeneca has opened its first U.S.-operated cell therapy manufacturing facility in Rockville, Maryland, as part of its ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

The facility, which will produce cell therapies used to treat cancer and auto immune diseases, creates 150 jobs for highly ...

The European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) ...

The facility to manufacture cell therapies for cancer research is part of the company's push to invest $3.5B in its U.S.

The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology." ...

Q1 2025 Management View CEO Eric Lefkofsky highlighted a record quarter for Tempus, with quarterly revenue increasing 75.4% ...

As it applies to the development of cell therapies, AstraZeneca’s chief of global operations, Pam Cheng, admits that the ...

AstraZeneca said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for ...

The chief executive of AstraZeneca said on Tuesday that the drugmaker will maintain its 2025 sales guidance even if the U.S.

The drugmaker posted increased core earnings per share and sales for the first quarter, but also said it could face a fine of ...

The company removed experimental drugs for Alzheimer’s, migraine and pain from its pipeline to focus more resources on “core ...